Eugene Yoshio Fukudome, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shock, Hemorrhagic | 10 | 2012 | 225 | 1.200 |
Why?
|
| Histone Deacetylase Inhibitors | 8 | 2012 | 777 | 0.840 |
Why?
|
| Valproic Acid | 6 | 2012 | 445 | 0.830 |
Why?
|
| Multiple Trauma | 4 | 2011 | 369 | 0.480 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2018 | 176 | 0.460 |
Why?
|
| Chemokine CXCL1 | 1 | 2012 | 102 | 0.390 |
Why?
|
| Hydroxamic Acids | 6 | 2012 | 483 | 0.390 |
Why?
|
| Acute Lung Injury | 2 | 2012 | 377 | 0.320 |
Why?
|
| Integrative Medicine | 2 | 2019 | 87 | 0.290 |
Why?
|
| Surgery, Plastic | 3 | 2019 | 651 | 0.290 |
Why?
|
| Hypothermia, Induced | 2 | 2010 | 752 | 0.280 |
Why?
|
| Hemorrhage | 1 | 2018 | 3461 | 0.250 |
Why?
|
| Shock, Septic | 4 | 2012 | 774 | 0.220 |
Why?
|
| Resuscitation | 5 | 2012 | 679 | 0.180 |
Why?
|
| Blood Transfusion | 4 | 2018 | 1297 | 0.180 |
Why?
|
| Rats, Inbred WKY | 4 | 2012 | 150 | 0.160 |
Why?
|
| Homeopathy | 1 | 2019 | 30 | 0.160 |
Why?
|
| Lipopolysaccharides | 6 | 2012 | 2216 | 0.160 |
Why?
|
| Postoperative Complications | 3 | 2019 | 15747 | 0.140 |
Why?
|
| Education, Medical, Graduate | 2 | 2019 | 2418 | 0.130 |
Why?
|
| Nitroglycerin | 1 | 2018 | 331 | 0.130 |
Why?
|
| Lung | 4 | 2012 | 10033 | 0.130 |
Why?
|
| Critical Care | 1 | 2009 | 2712 | 0.130 |
Why?
|
| Peroxidase | 4 | 2012 | 606 | 0.130 |
Why?
|
| Mind-Body Therapies | 1 | 2019 | 294 | 0.120 |
Why?
|
| Debridement | 1 | 2018 | 495 | 0.120 |
Why?
|
| Vasoconstriction | 1 | 2018 | 594 | 0.120 |
Why?
|
| Efficiency | 1 | 2018 | 480 | 0.120 |
Why?
|
| Research Support as Topic | 1 | 2018 | 696 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2018 | 988 | 0.110 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 598 | 0.100 |
Why?
|
| Receptors, GABA-B | 2 | 2003 | 59 | 0.100 |
Why?
|
| Microsurgery | 1 | 2018 | 795 | 0.100 |
Why?
|
| Drainage | 1 | 2018 | 1179 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 932 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 1078 | 0.100 |
Why?
|
| Ventral Tegmental Area | 2 | 2003 | 136 | 0.090 |
Why?
|
| Plasma | 2 | 2011 | 579 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2019 | 1456 | 0.090 |
Why?
|
| Publishing | 1 | 2018 | 835 | 0.090 |
Why?
|
| Rats | 5 | 2012 | 23707 | 0.080 |
Why?
|
| Ischemia | 1 | 2018 | 1909 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2018 | 2267 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 586 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 634 | 0.080 |
Why?
|
| Histone Acetyltransferases | 1 | 2010 | 332 | 0.070 |
Why?
|
| Disease Models, Animal | 7 | 2012 | 18293 | 0.070 |
Why?
|
| Blood Coagulation Disorders | 1 | 2011 | 349 | 0.070 |
Why?
|
| Mammaplasty | 1 | 2018 | 1264 | 0.070 |
Why?
|
| Hypothermia | 1 | 2009 | 190 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 612 | 0.070 |
Why?
|
| General Surgery | 1 | 2019 | 1722 | 0.070 |
Why?
|
| Epigenomics | 1 | 2012 | 959 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 583 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3615 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2010 | 1884 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 1240 | 0.060 |
Why?
|
| Animals | 17 | 2012 | 168764 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2019 | 6203 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 1731 | 0.060 |
Why?
|
| Histones | 2 | 2011 | 2584 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 10563 | 0.050 |
Why?
|
| Narcotics | 2 | 2003 | 332 | 0.050 |
Why?
|
| Motor Activity | 2 | 2003 | 2704 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 1042 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2018 | 8067 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2018 | 3458 | 0.050 |
Why?
|
| Random Allocation | 3 | 2011 | 2395 | 0.050 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2009 | 1002 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2012 | 12768 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2268 | 0.040 |
Why?
|
| Macrophages | 2 | 2012 | 5772 | 0.040 |
Why?
|
| Forecasting | 1 | 2009 | 2936 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2012 | 23601 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 7599 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2012 | 4348 | 0.040 |
Why?
|
| Pneumonia | 1 | 2011 | 2157 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2009 | 1950 | 0.040 |
Why?
|
| Nucleus Accumbens | 1 | 2002 | 360 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2009 | 1921 | 0.040 |
Why?
|
| Male | 15 | 2019 | 363698 | 0.040 |
Why?
|
| Cause of Death | 1 | 2009 | 3708 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 2019 | 166 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 7 | 2012 | 22332 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2011 | 5020 | 0.040 |
Why?
|
| Papaverine | 1 | 2018 | 45 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5302 | 0.040 |
Why?
|
| Liver | 2 | 2010 | 7562 | 0.040 |
Why?
|
| Patient Selection | 1 | 2009 | 4255 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2012 | 582 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2019 | 65188 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2018 | 508 | 0.030 |
Why?
|
| Interleukin-6 | 3 | 2012 | 3222 | 0.030 |
Why?
|
| Survival Rate | 4 | 2011 | 12795 | 0.030 |
Why?
|
| Industry | 1 | 2018 | 362 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2018 | 704 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 21056 | 0.030 |
Why?
|
| Outpatients | 1 | 2023 | 1595 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 791 | 0.030 |
Why?
|
| Mastectomy | 1 | 2023 | 1847 | 0.030 |
Why?
|
| Bibliometrics | 1 | 2018 | 357 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 990 | 0.030 |
Why?
|
| United States | 4 | 2019 | 72903 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 2844 | 0.030 |
Why?
|
| Necrosis | 1 | 2018 | 1617 | 0.030 |
Why?
|
| GABA-B Receptor Agonists | 2 | 2003 | 11 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2019 | 1470 | 0.030 |
Why?
|
| GABA Agonists | 2 | 2003 | 105 | 0.030 |
Why?
|
| Female | 7 | 2023 | 396112 | 0.020 |
Why?
|
| Mice | 8 | 2012 | 81819 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 75 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7851 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 4562 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 11888 | 0.020 |
Why?
|
| Baclofen | 2 | 2003 | 121 | 0.020 |
Why?
|
| Middle Aged | 4 | 2019 | 223009 | 0.020 |
Why?
|
| Adult | 4 | 2019 | 223044 | 0.020 |
Why?
|
| Citrulline | 1 | 2011 | 106 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2011 | 97 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 74840 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 431 | 0.020 |
Why?
|
| Swine | 2 | 2011 | 5988 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2002 | 3085 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 287 | 0.020 |
Why?
|
| Base Sequence | 2 | 2012 | 12403 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2003 | 576 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 422 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 1135 | 0.020 |
Why?
|
| Humans | 7 | 2023 | 765968 | 0.020 |
Why?
|
| Breast | 1 | 2018 | 1946 | 0.020 |
Why?
|
| Gene Expression | 2 | 2012 | 7584 | 0.020 |
Why?
|
| Acidosis, Lactic | 1 | 2010 | 144 | 0.020 |
Why?
|
| Morphine | 2 | 2003 | 660 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 171117 | 0.020 |
Why?
|
| Hemostasis | 1 | 2011 | 467 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2003 | 1417 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 691 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2009 | 261 | 0.020 |
Why?
|
| Linear Models | 1 | 2018 | 5876 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2009 | 430 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 399 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 507 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 414 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 3685 | 0.020 |
Why?
|
| Graft Survival | 1 | 2018 | 3890 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 1053 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3475 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2010 | 584 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 2825 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2010 | 798 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2011 | 1188 | 0.020 |
Why?
|
| Femoral Fractures | 1 | 2009 | 375 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2010 | 1090 | 0.010 |
Why?
|
| Apoptosis | 2 | 2011 | 9514 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2010 | 1183 | 0.010 |
Why?
|
| GABA-B Receptor Antagonists | 1 | 2003 | 11 | 0.010 |
Why?
|
| beta Catenin | 1 | 2009 | 1043 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2012 | 2485 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 1870 | 0.010 |
Why?
|
| GABA Antagonists | 1 | 2003 | 120 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 152 | 0.010 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 1028 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 1792 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8703 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 1410 | 0.010 |
Why?
|
| Neurons | 1 | 2002 | 9525 | 0.010 |
Why?
|
| Prevalence | 1 | 2019 | 15842 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3797 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2023 | 81514 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 1884 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4137 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2453 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3850 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 8278 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 4392 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5881 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2019 | 5946 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29922 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 3046 | 0.010 |
Why?
|
| Feedback | 1 | 2002 | 796 | 0.010 |
Why?
|
| Neural Inhibition | 1 | 2002 | 589 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 2077 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 18973 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39193 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15543 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14652 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2002 | 1175 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2002 | 1140 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 41649 | 0.010 |
Why?
|
| Dopamine | 1 | 2002 | 1582 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 16721 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9525 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 9443 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2009 | 8532 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 17075 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 11022 | 0.000 |
Why?
|